Drug Trial Radar · NCT05692180
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
94
Actual
Start
Apr 5, 2023
Primary completion
Dec 23, 2026
Study completion Dec 23, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jan 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.
Conditions
- Asthma
Interventions
BenralizumabDrug
Benralizumab active solution will be administered SC to the patients.
PlaceboDrug
Placebo solution will be administered SC to the patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first asthma exacerbationTime frame: From Baseline (Week 0) to End of Treatment (EOT) in DB treatment period
Locations
43 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Torrance, California
Research Site
Ocala, Florida
Research Site
Owensboro, Kentucky
Research Site
Lafayette, Louisiana
Research Site
Kansas City, Missouri
Research Site
Northfield, New Jersey
Research Site
The Bronx, New York
Research Site
Cincinnati, Ohio
Research Site
Charleston, South Carolina
Research Site
San Antonio, Texas
Research Site
Tyler, Texas
Research Site
Ciudad de Buenos Aire, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Florida, Argentina
Research Site
Lobos, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Mendoza, Argentina
Research Site
Mendoza, Argentina
Research Site
Rosario, Argentina
Research Site
San Juan Bautista, Argentina
Research Site
Santa Fe, Argentina
Research Site
Créteil, France
Research Site
Lyon, France
Research Site
Rouen, France
Research Site
Milan, Italy
Research Site
Roma, Italy
Research Site
Bialystok, Poland
Research Site
Krakow, Poland
Research Site
Lodz, Poland
Research Site
Skarżysko-Kamienna, Poland
Research Site
Tarnów, Poland
Research Site
Cheongju-si, South Korea
Research Site
Junggu, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Badalona, Spain
Research Site
Barcelona, Spain
Research Site
Benalmádena, Spain
Research Site
Esplugues de Llobregat, Spain
Research Site
Kaohsiung City, Taiwan
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.